These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23602984)

  • 1. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.
    Laprairie RB; Kelly ME; Denovan-Wright EM
    Neuropharmacology; 2013 Sep; 72():47-57. PubMed ID: 23602984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
    J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease.
    Chiodi V; Uchigashima M; Beggiato S; Ferrante A; Armida M; Martire A; Potenza RL; Ferraro L; Tanganelli S; Watanabe M; Domenici MR; Popoli P
    Neurobiol Dis; 2012 Mar; 45(3):983-91. PubMed ID: 22207189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
    Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.
    Naydenov AV; Sepers MD; Swinney K; Raymond LA; Palmiter RD; Stella N
    Neurobiol Dis; 2014 Nov; 71():140-50. PubMed ID: 25134728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
    Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin and cannabinoid receptors crosstalk in protection of huntingtin knock-in striatal neuronal cells in response to quinolinic acid.
    Zou S; Kumar U
    Neurochem Int; 2019 Oct; 129():104518. PubMed ID: 31381945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
    Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
    Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
    Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
    Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.
    McCaw EA; Hu H; Gomez GT; Hebb AL; Kelly ME; Denovan-Wright EM
    Eur J Biochem; 2004 Dec; 271(23-24):4909-20. PubMed ID: 15606779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous and synthetic cannabinoids induce the downregulation of cannabinoid CB1 receptor in retina.
    Papadogkonaki S; Theodorakis Κ; Thermos K
    Exp Eye Res; 2019 Aug; 185():107694. PubMed ID: 31199905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum.
    De Chiara V; Angelucci F; Rossi S; Musella A; Cavasinni F; Cantarella C; Mataluni G; Sacchetti L; Napolitano F; Castelli M; Caltagirone C; Bernardi G; Maccarrone M; Usiello A; Centonze D
    J Neurosci; 2010 Jun; 30(24):8127-37. PubMed ID: 20554863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
    Scotter EL; Goodfellow CE; Graham ES; Dragunow M; Glass M
    Br J Pharmacol; 2010 Jun; 160(3):747-61. PubMed ID: 20590577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of functional CB1 cannabinoid receptors in retinoic acid-differentiated P19 embryonal carcinoma cells.
    Svensson AC; Johansson M; Persson E; Carchenilla MS; Jacobsson SO
    J Neurosci Res; 2006 May; 83(6):1128-40. PubMed ID: 16477621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.
    Dowie MJ; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2010 Sep; 170(1):324-36. PubMed ID: 20600638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.
    Centonze D; Rossi S; Prosperetti C; Tscherter A; Bernardi G; Maccarrone M; Calabresi P
    Biol Psychiatry; 2005 Jun; 57(12):1583-9. PubMed ID: 15953496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists.
    Ribeiro R; Wen J; Li S; Zhang Y
    Prostaglandins Other Lipid Mediat; 2013 Jan; 100-101():1-14. PubMed ID: 23219970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.